Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Aug 28:20:100390.
doi: 10.1016/j.lrr.2023.100390. eCollection 2023.

Aggressive chronic lymphocytic leukemia masked by extensive marrow fibrosis

Affiliations
Case Reports

Aggressive chronic lymphocytic leukemia masked by extensive marrow fibrosis

Hareem Farooq et al. Leuk Res Rep. .

Abstract

Chronic lymphocytic leukemia (CLL) is one of the most common B-cell leukemias, occurring because of abnormal proliferation of non-functional B-lymphocytes. Progressive disease is commonly complicated by anemia, thrombocytopenia, infections as well as secondary malignancies. Bone marrow fibrosis is infrequently co-occurred along with CLL. Although multiple explanations have been proposed for this association, the etiology remains unclear in most cases. Bone marrow fibrosis occurring as a complication of CLL itself, however, is a rare entity. We present an uncommon case of a patient initially diagnosed with primary myelofibrosis but later revealed to have aggressive CLL leading to bone marrow fibrosis upon re-evaluation. Treatment for CLL resolved the bone marrow fibrosis completely, confirming our suspicion of fibrosis being secondary to CLL. This sheds light on the importance of understanding the etiology of bone marrow fibrosis in patients with CLL owing to its therapeutic implications. The utility of bone marrow biopsy in not only helping understand the etiology of the fibrosis but also providing prognostic information merits reconsideration of performing it in all cases of CLL.

Keywords: B-Cell; Bone marrow examination; Bone marrow fibrosis; Leukemia; Primary myelofibrosis.

PubMed Disclaimer

Conflict of interest statement

Talha Badar reports receiving honoraria/ serving in an advisory board for Pfizer-hematology and Oncology. Received Mayo Clinic Cancer Center Support Grant (CCSG) (P30 CA015083)

Figures

Fig 1
Fig. 1
Figure 1 (A) PET scan at diagnosis (B) Bone marrow biopsy reticulin stain at diagnosis (C) PET scan at completion of treatment (D) Bone marrow biopsy hematoxylin and eosin (H&E) stain at the end of treatment.

Similar articles

References

    1. Badar T., Burger J.A., Wierda W.G., O'Brien S. Ibrutinib: a paradigm shift in management of CLL. Expert Rev. Hematol. 2014;7:705–717. - PMC - PubMed
    1. Yao Y., Lin X., Li F., Jin J., Wang H. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed. Eng. Online. 2022;21:4. - PMC - PubMed
    1. Alaggio R., Amador C., Anagnostopoulos I., Attygalle A.D., IBdO Araujo, Berti E., et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–1748. - PMC - PubMed
    1. Tadmor T., Shvidel L., Aviv A., Ruchlemer R., Bairey O., Yuklea M., et al. Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications. Cancer. 2013;119:1853–1859. - PubMed
    1. Kimura A., Hyodo H., Nakata Y., Kuramoto A. Chronic lymphocytic leukemia associated with bone marrow fibrosis: possible role of interleukin 1 alpha in the pathogenesis. Am. J. Hematol. 1993;43:47–50. - PubMed

Publication types

LinkOut - more resources